Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02250105
Recruitment Status : Completed
First Posted : September 26, 2014
Last Update Posted : August 8, 2016
Sponsor:
Collaborator:
Baim Institute for Clinical Research
Information provided by (Responsible Party):
Arisaph Pharmaceuticals Inc

Brief Summary:
This study is to evaluate the efficacy and safety of ARI-3037MO 3g BID compared to placebo in reducing triglyceride (TG) levels of subjects with severe (≥500 mg/dL and <2,000 mg/dL) hypertriglyceridemia. Eligible patients will enter a 4- to 6-week lead-in period (6-week washout for subjects on non-statin lipid-lowering therapy [subjects may remain on statins during this period], 4 weeks for patients on statins only or not receiving any type of lipid-lowering therapy), followed by qualifying fasting TG measurements at visits 2 and 3, at least 7 days apart. If the baseline TG value is > 500 mg/dL and < 2,000 mg/dL, the qualified subjects will be randomized at visit 4 and enter the double-blind, 12-week efficacy and safety assessment phase. End-of-study lipid levels will be assessed on visits 6 and 7 (weeks 11 and 12 average). A final closeout and safety assessment visit will be done 14 weeks post randomization

Condition or disease Intervention/treatment Phase
Hypertriglyceridemia Drug: ARI-3037MO Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : September 2014
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Active Comparator: ARI-3037MO
ARI-3037MO 3g bid orally for 12 weeks
Drug: ARI-3037MO
Lipid lowering

Placebo Comparator: Placebo
Matching placebo 3g bid orally for 12 weeks
Drug: Placebo
Inactive




Primary Outcome Measures :
  1. Change in Triglyceride levels [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Change in LDL cholesterol [ Time Frame: 12 weeks ]
  2. Change in HDL cholesterol [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria 1. Age ≥ 18 years. 2. Subjects willing to comply with lifestyle intervention modifications (diet and exercise) 3. TG levels: At randomization, mean level > 500 mg/dL and < 2,000 mg/dL. 4. Understands the trial requirements and the treatment procedures, is willing to comply with all protocol-required follow-up evaluation and provides written informed consent.

5. Patients already taking statin therapy must be on a stable dose, defined as no changes in the dose of statin in the 3 months prior to enrollment, and must be willing and able to remain on that dose for the duration of the study.

-

Exclusion Criteria 1. History of pancreatitis. 2. Body mass index > 45 kg/m2. 3. Weight change ≥ 3 kg during the lead-in period. 4. Contraindication to niacin treatment (prior flushing is not regarded as a contraindication to niacin treatment).

5. Uncontrolled diabetes, defined as HbA1C > 10.5. 6. Subjects who would benefit from statin treatment per clinical guidelines but who are not taking statins are excluded. However, these patients may be included only if the subject's primary care physician confirms the decision not to treat according to guidelines and its reason (e.g. statin intolerant subjects, subject refusal, etc.), and it has been agreed upon by the subject, the site investigator, and the primary care physician, after discussion of the potential risks of non-treatment with statins..

7. History of stroke, myocardial infarction, life-threatening arrhythmia, or coronary vascularization within 6 months before screening.

8. Thyroid-stimulating hormone ≥ 1.5 times the ULN. 9. Clinical evidence of hypothyroidism or thyroid hormonal therapy that has not been stable for ≥ 6 weeks before screening.

10. Creatine kinase concentration ≥ 3 times the ULN. 11. Known, active liver disease, including but not limited to:

  1. Confirmed alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, or bilirubin ≥ 2 times the ULN.
  2. Hepatitis C (anti-hepatitis C virus IgG +).
  3. Hepatitis B (hepatitis B surface [HBs] antigen +, anti hepatitis B core [HBc] antigen immunoglobulin M [IgM]+).
  4. Hepatitis A (anti HBa IgM+). 12. Blood donation of ≥ 1 pint (0.5 L) within 30 days before screening or plasma donation within 7 days before screening.

    13. History of symptomatic gallstone disease unless treated with cholecystectomy.

    14. Known nephrotic syndrome or ≥ 3 g/day proteinuria. 15. Past organ transplant or on a waiting list for an organ transplant. 16. Currently receiving or scheduled to receive chemotherapy within 30 days before or after enrollment.

    17. Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 12 months.

    18. Problems with substance abuse, which, in the opinion of the investigator, might affect study compliance.

    19. Planned procedure that may cause non-compliance with the protocol or confound data interpretation.

    20. Current participation in another investigational drug or device clinical trial that has not reached its primary endpoint.

    21. Women who intend to become pregnant within 12 months after enrollment. Women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after enrollment.

    22. Women who are pregnant or nursing. 23. Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02250105


Locations
Layout table for location information
United States, California
Orange County Research Center
Tustin, California, United States, 92780
United States, Kentucky
Louisville Metabolic and Atherosclerosis Research Center
Louisville, Kentucky, United States, 40213
United States, Maine
Maine Research Associates
Auburn, Maine, United States, 04210
United States, Ohio
Sterling Clinical Research Inc
Cincinnati, Ohio, United States, 45219
United States, Virginia
National Clinical Research inc
Richmond, Virginia, United States, 23294
Sponsors and Collaborators
Arisaph Pharmaceuticals Inc
Baim Institute for Clinical Research
Layout table for additonal information
Responsible Party: Arisaph Pharmaceuticals Inc
ClinicalTrials.gov Identifier: NCT02250105    
Other Study ID Numbers: ARI-3037MO-004
First Posted: September 26, 2014    Key Record Dates
Last Update Posted: August 8, 2016
Last Verified: August 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertriglyceridemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases